Susquehanna International Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-13,300
| Closed | -$49K | – | 10795 |
|
|
2017
Q4 | $49K | Sell |
13,300
-25,700
| -66% | -$105K | ﹤0.01% | 8915 |
|
|
2017
Q3 | $160K | Buy |
39,000
+12,300
| +46% | +$47.1K | ﹤0.01% | 8160 |
|
|
2017
Q2 | $99K | Sell |
26,700
-45,000
| -63% | -$179K | ﹤0.01% | 8694 |
|
|
2017
Q1 | $297K | Buy |
71,700
+39,500
| +123% | +$166K | ﹤0.01% | 7354 |
|
|
2016
Q4 | $139K | Buy |
+32,200
| New | +$208K | ﹤0.01% | 8898 |
|
|
2016
Q2 | – | Sell |
-6,967
| Closed | -$53K | – | 9808 |
|
|
2016
Q1 | $53K | Sell |
6,967
-10,600
| -60% | -$81.6K | ﹤0.01% | 8652 |
|
|
2015
Q4 | $234K | Sell |
17,567
-9,900
| -36% | -$170K | ﹤0.01% | 8164 |
|
|
2015
Q3 | $452K | Sell |
27,467
-48,500
| -64% | -$994K | ﹤0.01% | 7315 |
|
|
2015
Q2 | $1.71M | Buy |
75,967
+68,800
| +960% | +$1.09M | ﹤0.01% | 5064 |
|
|
2015
Q1 | $70K | Buy |
7,167
+2,284
| +47% | +$22.4K | ﹤0.01% | 9074 |
|
|
2014
Q4 | $56K | Sell |
4,883
-35,000
| -88% | -$380K | ﹤0.01% | 9349 |
|
|
2014
Q3 | $459K | Sell |
39,883
-234
| -0.6% | -$3.57K | ﹤0.01% | 7366 |
|
|
2014
Q2 | $780K | Sell |
40,117
-16,450
| -29% | -$290K | ﹤0.01% | 6582 |
|
|
2014
Q1 | $1.01M | Buy |
56,567
+14,500
| +34% | +$238K | ﹤0.01% | 5500 |
|
|
2013
Q4 | $444K | Sell |
42,067
-41,000
| -49% | -$458K | ﹤0.01% | 6922 |
|
|
2013
Q3 | $1.03M | Buy |
83,067
+9,517
| +13% | +$100K | ﹤0.01% | 5226 |
|
|
2013
Q2 | $692K | Buy |
+73,550
| New | +$945K | ﹤0.01% | 5574 |
|
Susquehanna International Group's CASC Position: Q1 2018 in Review
Susquehanna International Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 57,192 shares — an estimated $212K sold.
Susquehanna International Group first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $934K in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Susquehanna International Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Susquehanna International Group sold 57,192 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $212K.
- Susquehanna International Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
- Susquehanna International Group's Cascadian Therapeutics, Inc. position peaked at $934K in Q1 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.